Price T Rowe Associates Inc Phathom Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 21,049 shares of PHAT stock, worth $157,867. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,049
Previous 20,575
2.3%
Holding current value
$157,867
Previous $212,000
79.72%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$75.8 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$56 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$44 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$30.7 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$26.2 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $294M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...